Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial.
Nineteen patients with severe or recalcitrant rosacea were treated twice daily with 0.75 percent metronidazole topical gel in an open label study. Sixteen of the patients (84 percent) showed 50 percent or greater reduction in inflammatory lesions, while fifteen (79 percent) demonstrated a reduction in erythema severity and an improvement when evaluated by the investigator global assessment. No positive response was recorded for any patient prior to topical medication, whereas six of nine patients previously treated with tetracycline/minocycline demonstrated improvement. Seven of these nine patients responded to topical metronidazole treatment. One additional patient who did not respond to minocycline or desonide treatment showed a good response to topical metronidazole. Only one patient reported local irritation after using metronidazole. These results demonstrate that topical metronidazole gel is safe and effective for the treatment of severe or recalcitrant rosacea.
Lowe
N J
NJ
Department of Dermatology, UCLA School of Medicine.
Henderson
T
T
Millikan
L E
LE
Smith
S
S
Turk
K
K
Parker
F
F
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005148:Facial Dermatoses / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D011446:Prospective Studies; D012393:Rosacea / Q000188:drug therapy*
D008795:Metronidazole